Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) SEC filings page on Stock Titan provides access to the company’s public filings and related disclosures as they appear in the U.S. Securities and Exchange Commission’s EDGAR system. Mirum is a biopharmaceutical and rare disease company with approved therapies such as LIVMARLI, CHOLBAM and CTEXLI and a pipeline that includes volixibat, brelovitug and MRM-3379, as described in its press releases.
Through this page, users can review Mirum’s current and historical filings, including Form 8-K reports that describe material events. Recent 8-K filings have covered topics such as an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, associated private placement subscription agreements, and corporate updates on financial results. Other 8-K disclosures include receipt of a Paragraph IV Certification Notice Letter related to a generic version of LIVMARLI and press releases furnished as exhibits discussing quarterly results.
Stock Titan enhances these documents with AI-powered summaries designed to highlight the main points of lengthy filings. For example, AI summaries can help readers quickly understand key terms of merger agreements, private placement structures, or the implications of patent-related notices referenced in Mirum’s 8-Ks. Users can also monitor unregistered sales of equity securities and other capital markets activities described in the filings.
This page updates as new Mirum filings are posted to EDGAR, giving investors and researchers a structured way to follow regulatory disclosures alongside the company’s rare disease commercial and development programs. Forms such as 10-K, 10-Q and additional 8-Ks, when available, can be reviewed with AI-generated insights to assist in interpreting Mirum’s reporting.
Mirum Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on three key items: electing three Class I directors to serve until 2029, ratifying Ernst & Young LLP as auditor for 2026, and approving, on an advisory basis, executive compensation.
The meeting will be held in person on June 15, 2026 at 9:00 a.m. Pacific Time at Mirum’s Foster City, California headquarters. Stockholders of record as of April 20, 2026 can vote by internet, telephone, mail, or in person, with one vote per share. A quorum requires at least 30,488,921 of the 60,977,841 shares outstanding.
Mirum highlights a classified board structure with an independent Chair, describes committee independence and risk oversight, and notes robust stockholder engagement representing more than 70% of shares in 2025. The company reports 2025 net product sales of $521.3 million and emphasizes a pay-for-performance program, with 92.5% of CEO pay and 84.1% of other named executive officer pay at risk through bonuses and equity awards.
Mirum Pharmaceuticals director Saira Ramasastry exercised options and sold the resulting shares in a planned transaction. On April 15, 2026, she exercised a stock option to acquire 2,000 shares of Mirum common stock at $23.51 per share, from a fully vested option. The same day, she sold 2,000 common shares in an open-market transaction at $96.90 per share, leaving 0 shares of common stock reported as directly owned after the sale. The filing notes the activity occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the trades were pre-arranged.
MIRM filer submitted a Rule 144 notice reporting an intended sale of 2,000 shares of Common Stock on 04/15/2026 via a Stock Option Exercise for cash. The filing also lists two recent sales: 2,000 shares on 03/16/2026 for $181,520 and 2,000 shares on 02/13/2026 for $204,180.
Mirum Pharmaceuticals filed an amended report to add full financial details for its acquisition of Bluejay Therapeutics and a related equity financing. The filing includes Bluejay’s audited 2025 statements, showing $85.6 million in assets and a net loss of $101.7 million, highlighting its clinical-stage profile.
The amendment also provides unaudited pro forma results combining Mirum and Bluejay and reflecting Mirum’s $280.8 million upfront cash paid in the deal and a concurrent private placement of 3,385,149 shares and 536,412 pre-funded warrants, which generated approximately $268.5 million in gross proceeds.
Mirum Pharmaceuticals Inc received an Amendment No. 1 Schedule 13G/A from The Vanguard Group describing an internal realignment under SEC Release No. 34-39538 (January 12, 1998). The filing states Vanguard and certain subsidiaries will report disaggregated holdings and that those subsidiaries pursue the same investment strategies. The filing reports amount beneficially owned: 0 and percent of class: 0% for Mirum common stock. The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Mirum Pharmaceuticals’ Chief Financial Officer Eric Bjerkholt exercised performance-based equity and sold shares mainly to cover taxes. He converted 13,334 performance restricted stock units into common stock at a conversion price of $0.0000 per unit. On the next trading day, 7,287 common shares were sold at an average price of $91.9779 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, he directly held 49,788 shares of Mirum common stock.
Mirum Pharmaceuticals chief medical officer Joanne Quan exercised performance-based stock awards and sold shares mainly to cover taxes. On March 15, 2026, she exercised 13,334 performance restricted stock units, receiving the same number of Mirum common shares at a $0 exercise price, leaving 6,666 units outstanding. On March 16, 2026, she sold 7,287 shares of common stock in an open-market transaction at an average price of $91.9779 per share to satisfy tax withholding obligations tied to the vesting. After these transactions, Quan directly owned 18,864 Mirum common shares. The remaining performance units are scheduled to vest with two-thirds on March 15, 2026 and one-third on March 15, 2027, as described in the filing.
Mirum Pharmaceuticals director Saira Ramasastry exercised stock options and sold the resulting shares. On March 16, 2026, she exercised options for 2,000 shares of common stock at an exercise price of $23.51 per share, then sold 2,000 shares in an open‑market transaction at $90.76 per share.
The filing shows she no longer directly holds these 2,000 common shares after the sale. The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.